Concepedia

Sabrina Baltschukat

SB

4

Publications

816

Citations

4

H-Index

2016

Active since

Affiliations

Novartis (Switzerland)(Current)

Sabrina Baltschukat is an author at Novartis (Switzerland) specializing in targeted therapy, cancer research, and cancer therapeutics.

ORCID

Top concepts

Publications per year

2016–2024

4

Publications

4

Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu et al. · Cancer Discovery · 2016 · 527 citations · Full text

Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang et al. · Clinical Cancer Research · 2019 · 171 citations

Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers

Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli et al. · Nature Cancer · 2024 · 104 citations · Full text

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Ralph Tiedt, Frederick J. King, Christelle Stamm et al. · Cell Reports · 2023 · 14 citations · Full text

, , +20

Rows per page

1–4 of 4